RxDoctor Payments Data

Samir Ouais, MD

Internal Medicine · Cleveland, TXNPI 1861559213

Payments from drug & device makers

$8,524in general payments, 2019–2025

Across 364 payments — averaging $23.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$1000
  • Bayer$696
  • Dexcom, Inc.$579
  • Amgen$559
  • AstraZeneca$475
  • Novo Nordisk$450
  • plus $5K from 47 others

What the payments were for

  • Food & beverage$8,506100%
  • Education$180%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,524 in reported general payments places this provider in the 90th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$19,113
Medicare patients
57
Services billed
144

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide196$316,097
MounjaroTirzepatide91$134,219
FarxigaDapagliflozin Propanediol96$107,373
KerendiaFinerenone49$66,320
JardianceEmpagliflozin59$66,258
TradjentaLinagliptin33$43,756
TrulicityDulaglutide17$36,374
JanuviaSitagliptin Phosphate27$20,529
Fiasp FlextouchInsulin Aspart (Niacinamide)17$19,996
Lantus SolostarInsulin Glargine,hum.Rec.Anlog119$18,340
Humalog Kwikpen U-100Insulin Lispro52$15,883
VascepaIcosapent Ethyl21$14,829
Soliqua 100-33Insulin Glargine/Lixisenatide13$12,058
Tresiba Flextouch U-200Insulin Degludec16$11,732
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog13$10,263

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$450$316,097196 claims
Lilly USA, LLCMounjaro, Trulicity$1,000$170,594108 claims
Boehringer IngelheimJardiance, Tradjenta$64$110,01392 claims
AstraZenecaFarxiga$475$107,37396 claims
BayerKerendia$696$66,32049 claims
MerckJanuvia$25$20,52927 claims
Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus$323$13,55436 claims
AbbVieSynthroid, Armour Thyroid$105$5,65473 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$51$2,366251 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Cleveland

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →